[MISSPELLED] UNI-PHARMA Pharmaceutical Laboratories S.A. is a leading Greek pharmaceutical company that researches, develops, manufactures, and distributes pharmaceuticals, food supplements, and medical devices. Established in 1964, it currently holds the first place in unit sales among purely Greek pharmaceutical companies.  Company Overview  Foundation and Ownership: Founded in 1964 by pharmacist Kleon Tsetis. It is part of the Tsetis Group of Pharmaceutical Companies (OFET) and is currently led by Julia Tseti, President & CEO. Market Position: It is a major player in the Greek market, serving homes and medical professionals with innovative, value-added products. International Recognition: UNI-PHARMA is an officially recognized supplier to international organizations, including the United Nations (UN), UNICEF, and the World Health Organization (WHO). Workforce: The company employs approximately 700 people and has been certified as a "Top Employer" in Greece for consecutive years (2023, 2024).  Core Product Portfolio  UNI-PHARMA produces several groundbreaking and well-known pharmaceutical products, including:  - T4 and Salospir. - Apotel (notably, the company holds a European Patent for injectable paracetamol solutions obtained in 1998). - Trebon and Trebon Grippe Day & Night. - Specialty items: Vitamins, probiotics, and products for joint, bone, and gastrointestinal health.  Philosophy and Values  The company follows the "TELEIA" (Greek for "perfect") philosophy, which stands for:  - Teamwork - Ethos (Ethics) - Learning - Excellence - Innovation - Accountability  Sustainability and CSR  UNI-PHARMA is a member of the UN Global Compact (joined in 2016) and integrates Sustainable Development Goals (SDGs) into its operations. Its bioclimatic plant is designed to optimize energy use and reduce environmental impact.